search
Back to results

Effect of Enteral Bovine Lactoferrin in Preterm Infants

Primary Purpose

to Evaluate the Effect of Oral Administration of Bovine Lactoferrin on the Neurobehavioral Performance of Preterm Neonates

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
bovine lactoferrin
Sponsored by
Ain Shams University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for to Evaluate the Effect of Oral Administration of Bovine Lactoferrin on the Neurobehavioral Performance of Preterm Neonates

Eligibility Criteria

1 Hour - 3 Days (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Stable preterm neonates gestational age less than 35 weeks younger than 72 hours at randomization have initiated enteral feds. Exclusion Criteria: 1. Neonates with underlying gastrointestinal problems that prevent oral intake. 2. Neonates with predisposing conditions that profoundly affect growth and development (chromosomal abnormalities, structural brain anomalies, severe congenital abnormalities). 3. Neonates with a history of perinatal hypoxia. 4. Neonates with a family background of cow milk allergy. 5. Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake.

Sites / Locations

  • Ain Shams University Hospitals

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

lactoferrin group

control group

Arm Description

Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer. (Asztalos.,et al 2020)

Neonates will receive their routine feds and will not receive lactoferrin.

Outcomes

Primary Outcome Measures

neurobehavioral outcome
The present study is designed to evaluate the effect of oral administration of bovine lactoferrin on the neurobehavioral performance of preterm neonates at 36 weeks corrected age using the Neonatal Intensive Care Unit Neurobehavioral Scale (NNNS).
Morbidity
Define any morbidities from oral lactoferrn administration
Mortality
To assess number of deaths in the study group

Secondary Outcome Measures

effect on morbidity and mortality
effect on mortality and major morbidity at 36 weeks corrected gestational age defined as periventricular leukomalacia, necrotizing enterocolitis, and late-onset sepsis.

Full Information

First Posted
July 16, 2023
Last Updated
August 22, 2023
Sponsor
Ain Shams University
search

1. Study Identification

Unique Protocol Identification Number
NCT06015828
Brief Title
Effect of Enteral Bovine Lactoferrin in Preterm Infants
Official Title
Effect of Enteral Bovine Lactoferrin on Neurobehavioral Performance of Preterm Infants
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
September 20, 2021 (Actual)
Primary Completion Date
September 20, 2022 (Actual)
Study Completion Date
April 20, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
There is a preference for using enteral bovine lactoferrin for preterm infants. Lactoferrin is a sialic acid-rich, iron-binding milk glycoprotein, known to have multifunctional health benefits, including its ability to modulate immune function and facilitate iron absorption, as well as its antibacterial and anti inflammatory actions. The study is an evaluation of the efficacy of enteral bovine lactoferrin on neurobehavioral performance in preterm infants.
Detailed Description
Over 15 million infants are born preterm < 37 weeks gestation worldwide. (World Health Organization et al., 2015). Lactoferrin is about 80- kilo dalton kDa glycoprotein composed of 703 amino acid residues and is a member of the transferrin family, As a member of the transferrin family of iron-binding proteins, lactoferrin shares more than 60% homology at the amino acid level with transferrin and a 77% homology exists between human and bovine species. (Karav et al., 2018). Human lactoferrin is the most abundant glycoprotein. It contains 1- 4 Sialic acid residues at the terminal position of N-linked glycan chains for each lactoferrin molecule. (Lonnerdal et al., 2011). Poly Sialic acid plays a critical role in neural development by modulating the adhesive property of neural cell adhesion molecule and is, therefore, implicated in a wide range of morphogenic events, including cell migration, neuronal outgrowth, path-finding, sprouting, regeneration, synaptic plasticity, and serving a "reservoir function" for neurotrophic factors. Sia, a key monomeric building block of poly Sialic acid, plays crucial roles in cell-to-cell interactions, neuronal outgrowth, modifying synaptic connectivity, and memory formation (Wang et al., 2012). An important functional property of lactoferrin is its high affinity for binding iron (Kumar et al.,2013). Iron is a ubiquitous metal that is essential for the function of all mammalian cells. Iron deficiency affects neuronal metabolism, neurotransmitter function, and myelination, which have the greatest impact on the brain during early neurodevelopment (Cheli et al., 2018). Lactoferrin is unique in that it contains 2 nutritional molecules of iron and Sialic acid, which are key components involved in early neurodevelopmental and cognitive function for infants (Chen et al.,2015). Lactoferrin is a bifidogenic glycoprotein found in all vertebrates and mammalian milk, leukocytes, and exocrine secretions (Chahine et al.,2012). Inflammation has an adverse impact on cognition, and IL-1β, IL-6, and tumor necrosis factor alpha TNF-α are closely associated with long-term potentiation (LTP) and synaptic plasticity (Özkorumak et al., 2019). Lactoferrin is an antimicrobial, antioxidant, anti-inflammatory iron-carrying (Ochoa et al., 2019).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
to Evaluate the Effect of Oral Administration of Bovine Lactoferrin on the Neurobehavioral Performance of Preterm Neonates

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Double-blinded randomized controlled trial Neonates will be randomized using closed envelopes into two groups
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
lactoferrin group
Arm Type
Experimental
Arm Description
Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer. (Asztalos.,et al 2020)
Arm Title
control group
Arm Type
No Intervention
Arm Description
Neonates will receive their routine feds and will not receive lactoferrin.
Intervention Type
Dietary Supplement
Intervention Name(s)
bovine lactoferrin
Intervention Description
Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.
Primary Outcome Measure Information:
Title
neurobehavioral outcome
Description
The present study is designed to evaluate the effect of oral administration of bovine lactoferrin on the neurobehavioral performance of preterm neonates at 36 weeks corrected age using the Neonatal Intensive Care Unit Neurobehavioral Scale (NNNS).
Time Frame
at 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.
Title
Morbidity
Description
Define any morbidities from oral lactoferrn administration
Time Frame
At 36 weeks corrected gestational age
Title
Mortality
Description
To assess number of deaths in the study group
Time Frame
36 corrected gestational age
Secondary Outcome Measure Information:
Title
effect on morbidity and mortality
Description
effect on mortality and major morbidity at 36 weeks corrected gestational age defined as periventricular leukomalacia, necrotizing enterocolitis, and late-onset sepsis.
Time Frame
at 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Hour
Maximum Age & Unit of Time
3 Days
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Stable preterm neonates gestational age less than 35 weeks younger than 72 hours at randomization have initiated enteral feds. Exclusion Criteria: 1. Neonates with underlying gastrointestinal problems that prevent oral intake. 2. Neonates with predisposing conditions that profoundly affect growth and development (chromosomal abnormalities, structural brain anomalies, severe congenital abnormalities). 3. Neonates with a history of perinatal hypoxia. 4. Neonates with a family background of cow milk allergy. 5. Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
maha mohamed, PHD
Organizational Affiliation
Ain Shams University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
dina shinkar, PHD
Organizational Affiliation
Ain Shams University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
mariam ibrahim, PHD
Organizational Affiliation
Ain Shams University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
mahmoud kofory, MB.,B.CH
Organizational Affiliation
Azhar University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ain Shams University Hospitals
City
Cairo
State/Province
Al Qahirah
ZIP/Postal Code
1825
Country
Egypt

12. IPD Sharing Statement

Learn more about this trial

Effect of Enteral Bovine Lactoferrin in Preterm Infants

We'll reach out to this number within 24 hrs